Nanjing, China – GemPharmatech Co., Ltd., a global leader in mouse model development and preclinical research services, has entered into a comprehensive strategic partnership with Goodwill E-Health Info Co., Ltd., a pioneer in clinical data governance and medical AI. The collaboration aims to create a cutting-edge, AI-enhanced Patient-Derived Xenograft (PDX) model database to accelerate cancer treatment innovation and translational medicine.

Under the agreement, the two companies will combine their respective expertise—GemPharmatech’s extensive PDX model library and preclinical evaluation platforms, and Goodwill’s clinical data infrastructure and AI capabilities—to drive advancements in precision oncology, clinical trial design, and real-world data research.

Central to the collaboration is the integration of Goodwill’s intelligent medical data platform with GemPharmatech’s PDX model database. The partnership will establish a standardized system for managing and analyzing multi-source clinical data—including electronic medical records, imaging, lab results, and omics data—enabling a seamless pipeline from clinical sample collection through model construction and drug application.

Goodwill will deploy its proprietary medical large model and DeepSeek-based machine learning algorithms to develop a multimodal biological computing platform for GemPharmatech. Using advanced tuning methods and historical datasets, the platform is expected to significantly improve predictive accuracy and reduce PDX model construction time by up to 30 percent, particularly in accounting for tumor heterogeneity. It will also support the development of drug-model matching algorithms to enable more effective pre-screening of treatment plans.

The collaboration will also result in a real-time data analysis system designed to assess model applicability, visualize efficacy predictions, and support decision-making for target discovery and compound screening. This system will combine GemPharmatech’s robust mouse model and PDX databases with Goodwill’s research big data infrastructure.

To strengthen translational medicine efforts, the companies plan to launch a shared research platform that connects clinical data and preclinical model systems. This platform will enable real-time exchange of multicenter clinical research data and support a full-spectrum approach to innovative drug development—from human sample collection to model validation and therapeutic discovery.

On the commercial side, the partnership will integrate PDX model services into Goodwill’s smart hospital research platform, offering pharmaceutical clients an end-to-end solution that includes model generation, data governance, and AI-powered efficacy predictions. Internationally, GemPharmatech’s presence in North America will complement Goodwill’s multicenter clinical trial data network, supporting the global standardization of PDX models in drug development pipelines.

By tightly aligning clinical and preclinical resources, the collaboration will establish a data-driven, closed-loop ecosystem for translational cancer research. High-quality human sample data, curated through Goodwill’s governance capabilities, will inform preclinical testing using GemPharmatech’s models, and the results will feed back into clinical optimization efforts through AI-enabled analysis. This continuous cycle is expected to accelerate therapeutic innovation and reshape how the biopharmaceutical industry moves from lab-based research to real-world clinical application.